Silicon Valley focuses on creating the ideal child

Imagine being able to select traits for your future child: a deep sleeper, a musical talent, or a knack for mathematics. For the founders of fertility tech startup Herasight, this is no longer just a thought experiment.

Founder Michael Christensen, standing at 6-foot-6, wants his future children to be shorter for more comfort on airplanes. Being extremely tall is inconvenient, he said. Tobias Wolfram, Herasights chief science officer, has already preserved embryos with his partner, aiming to reduce the risk of inheriting depression while benefiting from a family history of longevity and health. Meanwhile, communications executive Jonathan Anomaly, approaching 50, plans to screen for autoimmune conditions and moderate height for his future children.

This trend reflects a broader shift in the Bay Area, where affluent, tech-savvy parents are rethinking traditional reproduction. Instead of relying solely on natural conception, they are embracing IVF combined with advanced embryo screening to evaluate risks for inherited diseases, mental health conditions, and other traits such as height, IQ, and musical ability.

Some startups are pushing the boundaries further. Companies like Nucleus Genomics, funded by Alexis Ohanian, advertise embryo selection for desirable traits. Investments in fertility tech have surged, with 2024 marking $2 billion in funding for womens health and IVF-related startups.

Experts note that while some screenings are for curiosity or convenience, many parents seek to avoid passing on serious illnesses. Dr. Barry Behr of Stanford emphasizes that parents are motivated by the desire to prevent suffering, making embryo screening an ethical extension of care in many cases.

However, regulation has not kept pace with rapid innovation. Fertility lawyer Rich Vaughn points out that technology often develops faster than the law, creating legal and ethical challenges. Controversial practices such as embryo editingillegal in many countriesare attracting investment from high-profile figures including Brian Armstrong and Oliver Mulherin.

Other entrepreneurs, like Cathy Tie of Manhattan Genomics, are exploring gene correction before implantation to reduce inherited disease risk, starting with nonhuman primates before moving to humans pending approval. Support from researchers and IVF specialists underscores the growing interest despite ethical concerns.

Screening for cosmetic traits may be possible in the near future, but currently, most demand focuses on intelligence, mental health, and physical traits. Scientists caution that predicting behavioral or cognitive traits remains highly uncertain. Dr. Hank Greely notes that intelligence is influenced by numerous environmental and genetic factors, making designer babies for personality or IQ largely impractical for now.

Noor Siddiqui, founder of Orchid Health, uses polygenic screening primarily to prevent disease, inspired by her mothers genetic eye condition. Orchid offers whole-genome sequencing to identify thousands of genetic disorders, including mutations associated with autism, allowing parents to make informed decisions without guaranteeing a perfect child.

Herasight, which emerged from stealth mode, screens embryos for potential childhood and adult diseases, mental health conditions, height, IQ, and longevity. Studies suggest disease risks can be reduced by 20% to 44% when selecting among five embryos, though results are based on internal research. Founders emphasize that embryo selection often involves trade-offs, and perfection is unattainable.

While AI and genome sequencing promise greater predictive power, limitations remain. Kyle Farh of Illumina highlights the need for data from billions of genomes to improve prediction accuracy. Nevertheless, for families seeking to avoid serious hereditary diseases, the technology has already provided life-changing outcomes. Parents like Roshan George and Julie Kang successfully screened embryos to prevent profound deafness in their child, Astra.

Screening also offers hope for reducing pregnancy loss. Chromosomal abnormalities cause about half of first-trimester miscarriages, and selecting the healthiest embryos could increase the chances of successful pregnancies.

Despite ethical concerns, bioethicist Arthur Caplan warns that extensive embryo selection could pressure parents to view children as products with expected outcomes, potentially limiting freedom. Many prospective parents, like Victoria Fritz, approach embryo screening realistically, hoping for a healthy child rather than perfection.

As fertility technology advances, the focus remains on balancing innovation with ethics, offering families unprecedented control over health while navigating complex moral terrain.

Analysis: The Evolving Landscape of Fertility Technology and Its Ethical Implications

The rapid growth of fertility technology, particularly in embryo screening, represents a significant shift in how parents approach reproduction. What was once a futuristic concept is now becoming a reality, as companies like Herasight push the boundaries of genetic testing and embryo selection. For affluent and tech-savvy families, the ability to select for specific traits, such as height, intelligence, or mental health predispositions, offers an appealing level of control over their children's future. However, this raises complex questions about the ethical implications of such technologies.

While the motivation behind these technologies is often driven by the desire to prevent serious hereditary diseases, it is clear that the potential to select for non-medical traits—like physical appearance or cognitive abilities—could redefine the nature of parenthood. Parents like Michael Christensen and Jonathan Anomaly seek to mitigate personal inconveniences or improve their children's future quality of life. This shift in mindset reflects the changing attitudes in Silicon Valley, where technology is increasingly seen as a tool to improve human health and capabilities, rather than merely a means of overcoming disease.

However, as innovations in fertility technology outpace existing regulations, significant ethical dilemmas emerge. The possibility of “designer babies,” while not yet fully realized, presents a future where social pressures could push parents toward selecting only “optimal” traits for their children, potentially leading to a narrower view of human potential. Experts, like bioethicist Arthur Caplan, warn that such practices could commodify human life, reducing children to mere products of genetic engineering. These concerns are amplified by the fact that genetic predictions, particularly for complex traits like intelligence or behavior, remain highly uncertain and influenced by a multitude of factors beyond genetics.

The challenges posed by these technologies are not only ethical but also scientific. While genome sequencing and AI have shown promise in identifying potential genetic risks, their ability to predict non-medical traits, such as IQ or personality, is still far from reliable. Additionally, the data required to improve prediction accuracy remains scarce, with billions of genomes needed for more precise outcomes. Thus, while the technology offers exciting possibilities, it also highlights the limitations of current scientific understanding.

In conclusion, as the fertility tech industry continues to evolve, it is crucial to balance the potential benefits with the ethical risks. Parents are increasingly empowered to make informed decisions about their children's health, but the line between prevention and enhancement must be carefully considered. The future of reproductive technology lies not only in innovation but also in finding a responsible approach that respects both individual freedoms and the broader societal implications.

Sources:

• Silicon Valley sets its sights on building the perfect baby